Stock IdeasStrong Buy Stocks

Strong Buy Stocks from Top Wall Street Analysts

Latest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen

TD Cowen's Dan Brennan raised their price target on Guardant Health (NASDAQ: GH) by 3.8% from $130 to $135 on 2026/02/20. The analyst maintained their Strong Buy rating on the stock.

Guardant Health reported its Q4 and FY 2025 earnings.

Raising their price target, Brennan headlined that management provided "solid" FY 2026 guidance, "with Q4 top-line know, though true-ups more of a help."

The analyst said the highlight of the print was the 2026 Screening segment guidance, which included considerable investment in the sales force.

Earnings Report

Guardant Health reported:

For Q4 2025:

• Loss per share of $0.50, which missed the Zacks Consensus Estimate of $(0.42) but beat, by 19.4%, Q4 2024’s $(0.62).
• Revenue of $281.27M, which beat the Zacks Consensus Estimate by 0.47% and, by 39%, Q4 2024’s $201.81M.

For FY 2025:

• Loss per share of $1.82, compared to FY 2024’s loss of $2.01.
• Revenue of $982M, up 33% Y/Y.

For FY 2026, management guided:

• Revenue of $1.25B to $1.28B.

Co-founder & Co-CEO Helmy Eltoukhy commented: “We delivered an outstanding end to a great year, with Q4revenue growth of 39% Y/Y.

“Our progress in 2025 is a testament to our breakthrough innovation and best-in-class execution across our portfolio. 

“We are uniquely positioned with scaled offerings spanning both therapy selection and monitoring, and the recent launch of Reveal for therapy response monitoring further strengthens our competitive moat. 

“We look forward to another strong year ahead, supported by a diverse set of growth catalysts across our business.”

Co-founder & Co-CEO AmirAli Talasaz added, “Shield has become one of the most successful diagnostic launches, with meaningful volume and revenue generation in 2025 that exceeded our expectations.

“We are proud of the level of impact we have had to date, our commercial performance, and the strong operational foundations we’ve built to support the growing demand for Shield. 

“We are excited to deliver another year of significant growth in 2026, fueled by our expanding commercial infrastructure and a pipeline of growth drivers in front of us.”